Trial Profile
Chemotherapy in hormone-refractory prostate cancer: Docetaxel with and without VT122
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2013
Price :
$35
*
At a glance
- Drugs Propranolol/etodolac (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Vicus Therapeutics
- 20 Jun 2013 New trial record